Stockscreener 앱 받기
51.40
0.49%
0.25
Corcept Therapeutics Inc 주식(CORT)의 최신 뉴스
Zacks Research Has Negative Outlook for CORT Q1 Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - MSN
Community Spotlight: Breakthrough Type 1 Diabetes Walk - AOL
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes - Yahoo Finance
Korlym shows promise in Cushing's syndrome study By Investing.com - Investing.com Canada
Verition Fund Management LLC Sells 28,931 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes - BioSpace
Corcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in Study - MarketWatch
Korlym shows promise in Cushing's syndrome study - Investing.com
Corcept's Korlym Shows Breakthrough Results in Phase 4 Diabetes & Cushing's Trial, Hits Key Endpoint - StockTitan
Corcept Therapeutics Fall 3.5 After ALS Drug Fails Trial - MarketWatch
Corcept Phase 2 study of ALS drug fails to meet primary endpoint (NASDAQ:CORT) - Seeking Alpha
Corcept's ALS trial misses primary goal, notes survival difference By Investing.com - Investing.com Canada
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) - Yahoo Finance
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock - Yahoo Finance
Executive Wealth Management LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Tanaka Capital Management Inc. Purchases 11,860 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Two Sigma Advisers LP Has $21.16 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High? - MSN
Fmr LLC Boosts Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
What Makes Corcept (CORT) a Good Fit for 'Trend Investing' - Yahoo Finance
Corcept Therapeutics stock soars to all-time high of $61.67 By Investing.com - Investing.com Nigeria
Corcept Therapeutics stock soars to all-time high of $61.67 - Investing.com India
Jacobs Levy Equity Management Inc. Acquires 352,947 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump - Simply Wall St
Captrust Financial Advisors Sells 19,255 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
BNP Paribas Financial Markets Has $4.63 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years - Yahoo Finance
Cushing's Syndrome Market is expected to reach US$ 291.1 million - openPR
Charles Schwab Investment Management Inc. Has $47.51 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Algert Global LLC Increases Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief accounting officer sells $80,031 in stock - Investing.com India
Gary Charles Robb Takes Money Off The Table, Sells $146K In Corcept Therapeutics Stock - Benzinga
Corcept Therapeutics: A Most Promising And Compelling Biotech (NASDAQ:CORT) - Seeking Alpha
Corcept therapeutics executive sells $146,625 in stock By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Natixis Advisors LLC - Defense World
Corcept therapeutics executive sells $146,625 in stock - Investing.com India
StockNews.com Downgrades Corcept Therapeutics (NASDAQ:CORT) to Buy - Defense World
Corcept Therapeutics' chief accounting officer sells $80,031 in stock By Investing.com - Investing.com Australia
2.88%
2.65%
자본화:
|
볼륨(24시간):